1. 0.0-AML-Home
2. 1.0-Efficacy-OS
3. 1.1-Remission
4. 1.2-Hematologic-recovery
5. 1.3-Transfusion-independence
6. 1.4-EFS
7. 1.5-RWE
8. 1.6-Safety
9. 10.0-Safety
10. 11.0-Dosing
11. 12.0-IDH1-mutations
12. 12.1-MOA
13. 13.0-GUIDELINES
14. 14.0-MDS_AML
15. 14.1-AML-genetic-abnormalities
16. 15.0-MDS-INDICATION-SUMMARY
17. 2.0-Remission
18. 2.1-Duration-of-response
19. 2.2-Time-to-response
20. 2.3-Transfusion-independence
21. 2.4-Hematologic-parameters
22. 2.5-Safety
23. 3.0-Remission
24. 3.1-Duration-of-response
25. 3.2-Time-to-response
26. 3.3-Transfusion-independence
27. 3.4-OS
28. 3.5-Hematologic-recovery
29. 3.6-Safety
30. 4.0-Dosage-regimen
31. 4.1-Dosing-guidance
32. 5.0-mIDH1
33. 5.1-MoA
34. 5.2-Testing
35. 6.0-GUIDELINES
36. 7.0-INDICATIONS-SUMMARY
37. 8.0-MDS-Home
38. 9.0-Unmet-need
39. 9.1-Remission
40. 9.2-Overall-response
41. 9.3-Time-to-response
42. 9.4-Transfusion-independence
43. 9.5-Hematologic-recovery
44. 9.6-Overall-survival
45. shared